Astellas Pharma Inc.
FY2027 First Quarter IFRS (Consolidated) Financial Summary
Net sales 640,914 million yen (up 26.7% YoY), Core operating profit 221,417 million yen (up 55.6%), Core quarterly profit 170,472 million yen (up 62.8%). Full-year forecast for 2027: net sales 2,220,000 million yen, core operating profit 620,000 million yen, core net income 460,000 million yen. Dividend forecast for the fiscal year ending March 2027 remains at 80 yen (flat year over year).
Key Figures
- Net sales: 640,914 million yen
- Core operating profit: 221,417 million yen
- Core quarterly profit: 170,472 million yen
AI要約
Performance overview
This quarter's net sales expanded, with significant contributions from key strategic products such as PADCEV, IZERVAY, VYLOY, VEOZAH, XOSPATA, and XTANDI. Net sales were 640,914 million yen, with core metrics on a subtotal basis also markedly improved. Core operating profit was 221,417 million yen, and core quarterly profit was 170,472 million yen, demonstrating growth that more than offset currency effects and SG&A increases.
Outlook and dividend
The full-year forecast remains unchanged: net sales 2,220,000 million yen, core operating profit 620,000 million yen, and core net income 460,000 million yen, with an expectation of stable growth. Dividend for the fiscal year ending March 2027 is expected to be 80 yen, including the year-end dividend, totaling 80 yen for the year.
Net Sales Trend
Core Operating Profit Trend
Core Net Profit Margin
Geographical Revenue Composition
Astellas Pharma Inc.
Company overview · Stock price · Financial data · All IR
